When are alternative funding arrangements the right choice?
Across the U.S., CFOs, HR Directors, and CEOs at companies of all sizes are grappling with what to do in the face of unsustainable health insurance program…
By Ryan Cronan and George Lucas |
November 25, 2019 at 12:24 PM
Thank you for sharing!
Your article was successfully shared with the contacts you provided.
This recent headline in the Washington Post, “FDA approves a gene therapy that is the most expensive drug in the world,” perfectly underscores the situation. The gene-therapy, called Zolgensma, comes with a $2.1 million price tag to treat spinal muscular atrophy.
Complete your profile to continue reading and get FREE access to BenefitsPRO.com, part of your ALM digital membership.
Your access to unlimited BenefitsPRO.com content isn’t changing. Once you are an ALM digital member, you’ll receive:
Critical BenefitsPRO.com information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events.
Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com